Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number Substitute for form 1449/PTO

> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known Application Number 10/599,707 Filing Date October 5, 2006 First Named Inventor Lvn Howard Jones Art Unit 1614 Examiner Name TRA Attorney Docket Number PC32041A

EXAMINER Cite DOCUMENT Publication Date INITIAL No. 1 NUMBER MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number-Kind Code ²			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	AA	6,933,312	08-23-2005	Agouron Pharmaceuticals, Inc.	
	AB	10/657,033	09-05-2003	Pfizer Limited	
	AC	6,586,430	07-01-2003	Pfizer, Inc.	
	AD	2004/122064	06-24-2004	Glaxo Smith Kline	
	AE	3,303,200	02-07-1967	American Home Products Corporation	
	AF	6,518,293	02-11-2003	Hoffmann-LaRoche, Inc.	
	AG	6,833,364	12-21-2004	Bayer HealthCare AG	
	AH	6,518,293	02-11-2003	Hoffmann-LaRoche, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	No.1	Foreign Patent Document Country Code ³ Number ⁸ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	Al	GB223234	06-04-03	Pfizer Limited		L
	AJ	WO 91/11172	08-08-1991	The University of Kansas		
	AK	WO 94/02518	02-03-1994	The University of Kansas		L
	AL	WO 98/55148	12-10-1998	Janssen Pharmaceutica		L
	AM	WO 02/04424 A1	01-17-2002	Pfizer Limited		L
	AN	WO 2004/031178	04-15-2004	Pfizer Limited		

FXAMINER:

DATE CONSIDERED:

EXAMPER: Initial if reference consists not, whether or not exists no no conformance with 1999 600. Down line through challen of not in conformance and not considered, lack his copy of this form with next communication to EXAMPLE: Initial further consistent, whether on and obtains are continuous with 1972 WHI. Does her through collision that in continuous and an examinate copy of this hors with a continuous and a special polypoint.

Applicate Vision is various citatic designation contact organized "See Kind Calculo and 2017 DN hand because a grean pulgaging on MIPS 90 LOI "See Calculo the mount of an electracy by the two-lever code (WIDO Standard ST3). The function received in the contract of a contract, by the two-lever code (WIDO Standard ST3), "the function received description," in the contract of The collection of information is required by 37 CFR 197 and 196. The information is required to obtain or notion is benefit by the public, which is the (and by the USPTO to process) an excitation. Confidentially is

governed by SU SU 22 and ST CFE1 II. The collection is estimated in take 2 fewers to complete, making galaxies; preparing passion, inclinating the completing physiotism form to the USFTO. There will vary depending specific depth of the contraction of the manufact afficiency as greater to supplicate form to the USFTO. The will vary depending specific depth of the contraction of the manufact afficiency and a supplication for the Contraction of the manufact afficiency and the supplication for the Contraction of the manufact afficiency of the Contraction of th

Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known 10/599,707 Application Number Filing Date October 5, 2006 First Named Inventor Lvn Howard Jones Art Unit 1614 Examiner Name TRA Attorney Docket Number PC32041A

AO	WO 02/34745	05/02/2002	Anormed Inc.		
AP	GB223232	10/07/2002	Pfizer Limited		
AQ	WO 02/085860	10/31/2002	Jones, et al		
AR	WO 2006/072833	07-13-2006	Pfizer Limited		
AS	WO 2006/067587	06-29-2006	Pfizer Limited		
AT	WO 2004/031156	04-15-2004	Pfizer Limited		
AU	EP 0 786 455	07-30-1997	Shionogi & Co., Ltd.		
AV	WO 02/30907 A1	04-18-2002	F. Hoffmann-La Roche		
AW	WO 02/02524	01-10-2002	F. Hoffmann-La Roche		
AX	WO 02/100853	12-19-2002	F. Hoffmann-La Roche		
AY	WO 02/42279	05-30-2002	F. Hoffmann-La Roche	Derwent Abstract Enclosed	
AZ	WO 00/06569	02-10-2000	Baver Aktiengesellschaft	Derwent Abstract Enclosed	
BA	WO 98/16507	04-23-1998	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BB	WO 00/21954	04-20-2000	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BC	WO 02/42300	05-30-2002	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BD	WO 02/42302	05-30-2002	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BE	WO 02/42301	05-30-2002	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BE	DE 198 34 047 A	02-03-2000	Bayer AG	Derwent Abstract Enclosed	_
BG	WO 00/06567	02-10-2000	Bayer Aktiengesellschaft	Dervent Abstract Enclosed	_
BH	WO 98/23619	06-04-1998	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	_
 			_ aayaaaagesensonan		_

FXAMINER:

DATE CONSIDERED:

EXAMPER: Initial if reference considered, whether or not estables in meanfactures with 1999-600. Down line through challes of out in conformance and not considered, lackale copy of this form with next communication to EXAMPLE: Initial further consistent, whether on and obtains are continuous with 1972 WHI. Does her through collision that in continuous and an examinate copy of this hors with a continuous and a special polypoint.

Applicate Vision is various citatic designation contact organized "See Kind Calculo and 2017 DN hand because a green gauging on white 90 to 10 and 10 feet to most the forecast, by the two-lever code (WTD)

Standard 513, "five funness princip description, the most than the green of the right of the Trapeors must provide the existing and description." A white description is provided to the contract of the princip description. The princip description is a manufacture of the princip description of the princip description. The princip description is a manufacture of the princip description of the princip description. The princip description is a manufacture of the princip description is a manufacture of the princip description of the princip desc

The collection of information is required by 37 CFR 1-97 and 1-96. The information is required to obtain or notion is benefit by the public, which is the (in all by the USPTO to process) on excitation. Confidentially is governed by SU SU 22 and ST CFE1 II. The collection is estimated in take 2 fewers to complete, making galaxies; preparing passes and institute the count of the collection in collection is estimated by take 2 few support of the collection in the collection is estimated by take 2 few support of the collection in the collection is estimated by take 2 few support of the collection in the collection is estimated by the collection is es Information Disclosure Statement Page 2 of 4

Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number. Substitute for form 1449/PTO Complete if Known

	Application Number	10/599,707
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	October 5, 2006
	First Named Inventor	Lyn Howard Jones
	Art Unit	1614
(Use as many sheets as necessary)	Examiner Name	TBA
	Attorney Docket Number	PC32041A

ВІ	WO 99/54296	10-28-1999	Shionogi & Co.	
ВЈ	WO 2004/024147	03-25-2004	Pfizer Limited	

NON PATENT LITERATURE DOCUMENTS Cite include name of the author (in CAPITAL LETTERS). Sile of the article (when appropriate), title of the item (book Initials No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published, BERGE, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 1977, 1-19, vol. 66. RK no. 1. CHAN, J., et al., "Novel Benzophenones as Non-nucleoside Reverse Transciptase Inhbitors Of RI HIV-1," Journal Of Medicinal Chemistry, 2004, 1175-1182, vol. 47 CLERCO DE. E., "New Developments In Anti-HIV Chemotherapy," Current Medicinal Chemistry, BM 2001, 1543-1572, vol. 8, no. 13, FERRIS, R., et al., "Antiviral Activity Of GW678248, A Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor," Antimicrobial Agents And Chemotherapy, 2005, 4046-4051, vol. RN GENIN, M. et al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus The Delayirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," Journal of Medicinal Chemistry, BC 2000. 1034-1040. vol. 43. HAJIMORAD, et al., "Some Observations On The Binding Properties Of Alfalfa Moseic Virus To BP Polystyrene And Its Significance To Indirect ELISA," Archives of Virology, 1991, 219-235, vol. 117. OHKAWA, T., et al., "Structural Determination Of Metabolites Of S-1153, AA New, Potent, Non-Nucleoside, Anti-HIV Agent In Rath Liver Microsomes," Xenobiotica, 1998, 877-886, vol. 28, no. 9. BO RR STANOVNIC, et al., Science of Synthesis, 2002, 15-225, vol. 12.

EXAMINER:	DATE CONSIDERED:

Topics in Chemistry, Chapter 31, 306-316, (Not Available)

EXAMPER: Initial if reference consists not, whether or not exists no no conformance with 1999 600. Down line through challen of not in conformance and not considered, lack his copy of this form with next communication to applicant. Populsar's support entries designation matter (applicant) is a facility for the properties of the properties

ased by 37 CFS 197 and 1 98. The information in required to obtain or return a benefit by the public, which is to file (and by the USPTO to process) on medication in Confidentiality is governed by SU SC 122 and 37 CFR 114. This collection is estimated that take 2 hours to complete, metaloling gathering, preparing, and admitting the completed applications form to fix USP10. There will very objecting upon the relative has been seen and the complete applications for an other properties and the contract of the Contrac U.S. Department of Companies, Westmanner, O.C. 20231. DO NOT SEND PRES OR COMPLETED PORTES TO THIS ADDRESS. Send on Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22353 1450.

R2

Approved for use through 04/30/03. OMB 0851-0031
U.S. Palaria framerins (Total, U.S. Department of Commercial
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless collections as via 100 Mile control Number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/599,707	
INFORMATION DISCLOSURE	Filing Date	October 5, 2006	
	First Named Inventor	Lyn Howard Jones	
STATEMENT BY APPLICANT	Art Unit	1614	
(Use as many sheets as necessary)	Examiner Name	TBA	
	Attorney Docket Number	PC32041A	

вт	WAHHAB, A., et al., "Imidazole Based Non-peptide Angiotensin II Receptor Antagonists: Investigation Of The Effect Of The Orientation Of The Imidazole Ring On Biological Activity," Arzneimitel-Forschung, 1993, 1157-1168, vol. 43, no. 11
BU	WYAIT, P., et al., "Benzophenone Derivatives: A Novel Series Of Potent And Selective Inhibitors Of Human Immunodeficiency Virus Type 1 Reverse Transciptase; Journal Of Medicinal Chemistry, American Chemical Society, 1995, 1657-1665, vol. 38, no. 10.

EXAMINER:	DATE CONSIDERED:

DANCES, besid for future consistent, whether or not official in monthment with MIPP-00. Due for though chains for the medicaness and not modelled. But had not proposed by the proposed of the consistency of the future of the proposed of th

The effective of streaments required by \$1.70 (\$1.97 and \$1.98. The effectiveness required relative various breading by the global couldn't be the fixed by the USPUD by personal or application. Confidentially as presented by \$51.50 (\$1.90 and \$1.97 \$1.91 th). The meltiness desirable above the present position of a contrast of \$1.90 and \$1.90 an